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Abstract
Background: Integrins are used as prognostic indicators in breast cancer. Following engagement with extracellular
matrix proteins, their signaling influences numerous cellular processes including migration, proliferation, and death.
Integrin signaling varies between cell types through differential expression of integrin subunits, and changes within
a given cell upon exposure to a cell agonist or through changes in its surroundings. These variations in signaling
can profoundly affect the phenotypic, tumorogenecity and metastatic properties of cancer cells. In the present
study, we investigated if there were differences in the expression of integrins, integrin structures, and integrin co-
receptors within three breast cancer cells and if these differences effected integrin signaling.
Methods: Expression of integrins, urokinase receptor and vascular endothelial cell growth factor receptor (VEGFR)
in metastatic MDA-MB-435 and MDA-MB-231, non-metastatic MCF7 and non-breast cancer Hek-293 cells was
measured by flow cytometry. Cell adhesion was assessed using collagen, fibrinogen, fibronectin and vitronectin
coated plates. Changes in kinase levels following PMA stimulation, and cell adhesion-induced activation of kinases
were determined by western blot analysis. Distribution of actin stress fibers and focal adhesions was assessed by
immunocytochemistry.
Results: All cells expressed av integrins, while high b5 and avb5 expression was restricted to the cancer cells and
high b3 and avb3 expression was restricted to MDA-MB-435 cells. The two metastatic cells were the least adhesive,
but all cells adhered well to most proteins in the absence of PMA. All proliferating cells expressed activated pSrc,
but only proliferating metastatic cells expressed high pMEK levels. PMA treatment resulted in time-dependent
changes in activated kinase levels, and only MDA-MB-231 cells constitutively expressed high levels of activated
pMEK. MDA-MB-435 cells formed more stress fibers and focal adhesions and only exhibited adhesion-induced
activation of pMEK and pFAK. All cells expressed the urokinase receptor, but MCF7 cells had markedly higher
VEGFR expression. Adhesion induced differential expression of pFAK, pMEK and pERK.
Conclusions: This study demonstrates that breast cancers vary in their expression of integrins, their capacity to
form focal adhesion and to signal through integrins. These differences likely contribute to phenotypic variations
between cancer lines and account for some of the heterogeneity of breast cancer.
Background
Breast cancer is one of the most common cancers and
continues to rank as one of the top causes of death in
women [1]. The high mortality rate associated with
breast cancer is directly related to its ability to readily
metastasize. Histological type, size of tumor, metastasis,
epidermal growth factor receptor 2 (ErbB2) expression
and lymph node involvement are key factors used to
assess prognosis and probability of response to systemic
therapies [2]. However, breast cancer patients under-
going treatment continue to have different clinical out-
comes, despite having similar clinical diagnostic and
prognostic profiles. These differences in outcomes
underscore the heterogeneity of the disease, and the lim-
itation of using a mainly morphology-based classification
system for breast cancer [3]. To improve the classifica-
tion of breast cancers and the use of breast cancer ther-
apeutics, investigations into the biological mechanisms
underlying breast cancer have identified new and more
accurate biological markers and factors of breast cancer.
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rins, p53, urokinase plasminogen activator (uPA), uPA
inhibitor-1 and urokinase receptor (uPAR) have been
validated as biological prognostic markers in breast can-
cer [4]. Amongst these factors, integrins are a family of
cell adhesion receptors that are implicated in the estab-
lishment, metastasis and progression of many cancers
[5-9].
Integrins meditate cell adhesion to the cell-extracellu-
lar matrix (ECM), a fundamental cellular process that
not only regulates cell growth, differentiation, and death,
but also regulates malignant cell growth, metastasis and
cancer-induced angiogenesis [8,10,11]. Integrins partici-
pate in these cellular processes by providing a dynamic
physical linkage between the ECM and the actin cytos-
keleton. Engagement of integrins with ECM ligands trig-
gers integrin clustering, and the formation, disassembly
and reorganization of actin filaments, stress fibers and
focal adhesion complexes [7,12]. This dynamic reorgani-
zation of these cellular structures allows integrins to
function as regulators of cell shape and cellular pro-
cesses requiring cellular reshaping such as cell adhesion,
cell migration and cell division. Integrin clustering and
focal adhesions also elicit the activation of a number of
intracellular signaling pathways to regulate cytoskeletal
and ECM assembly, cell migration, proliferation, differ-
entiation and death [7,12]. As the cytoplasmic domain
of integrins lacks an actin binding domain and is devoid
of enzymatic activity, all these effects are mediated by
integrin associated molecules. The integrin associated
adhesion proteins that participate in this integrin-actin
linkage include the cytoskeletal proteins a-actinin, talin,
a n ds k e l e m i n ,a n dt h ek i n a s e si n v o l v e di ni n t e g r i ns i g -
naling include C-terminal Src kinase, focal adhesion
kinase (FAK), integrin linked kinase, and Src [8]. FAK is
a non-receptor protein tyrosine kinase that plays an
important role in the localization of integrins to focal
adhesions and the assembly of integrin-signaling mole-
cules [12]. It is involved in anchorage dependent survival
signaling and cell adhesion induces FAK autophosphory-
lation at tyrosine 397 (Y397), which creates a binding
site for Src, C-terminal Src kinase, GRB7, phosphatidyl
inositol 3 kinase, and phospholipase Cg. Subsequently,
Src phosphorylates FAK at a number of tyrosines
including Y925 that serves as binding site for GRB2,
which links integrins to the MAP kinase pathway [12].
Integrin signaling through Src can also be FAK-indepen-
dent as Src also binds constitutively and directly to b3,
and clustering of b3 integrins induces autophosphoryla-
tion and activation of Src [13]. The dynamics of integrin
signaling is further complicated by its cross-talk with
other receptors, including the breast cancer marker,
uPAR, and vascular endothelial cell growth factor recep-
tor (VEGFR) [11,14].
In this study a series of experiments were performed
to better understand the role of integrin-associated pro-
teins and structures, and integrin signaling pathways in
breast cancer. A non-breast cancer line, Hek-293, and
three breast cancer lines of differing metastatic and
invasive capacities were used: MDA-MB-435 that are
estrogen receptor-negative and highly metastatic; MDA-
MB-231 that are estrogen receptor-negative and highly
invasive; and, MCF7 that are estrogen receptor-positive
and non-metastatic [15-17]. We determined the levels of
integrins expressed by each cell line, and the capacity of
a cell agonist to stimulated cell adhesion to integrin
ligands and to induce intracellular signaling. We also
assessed the capacity of various ECM ligands to induce
heterogeneity into the formation and distribution of
integrin-associated structures and proteins within the
cells. Finally, we determined the levels of uPAR and
VEGFR expressed by the cell lines and the capacity of
cell adhesion to induce intracellular signaling via integ-
rin-linked Src and MAPK pathways.
Methods
Antibodies, Reagents, Chemicals
Antibodies against b3 (sc-6627), Bcl2 (sc-509), c-Src (sc-
8056), ERK (sc-94), FAK (sc-557), pFAK(Y397) (sc-
11765), pFAK(Y861) (sc-16663), pErbB2(Y1221/Y1222)
(6B12), VEGF (sc-80435), VEGFR2 (sc-57136), uPAR (sc-
13522), talin (sc-7534) and HRP secondary antibodies
were obtained from Santa Cruz (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA); b1 (MAB2253), b6
(MAB2076Z), avb3 (LM609), avb5 (MAB2019Z) and avb6
(MAB2074Z) from Millipore (Millipore Canada Ltd., Eto-
bicoke, ON); b3 (MHCD6100) from Invitrogen (Invitro-
gen Canada Inc., Burlington, ON); b5 (B5-IVF2) from
Abcam (Abcam Inc., Cambridge, MA); MEK, pMEK
(S217/S221); c-Src (36D10), pSrc(Y416) (100F9), pSrc
(Y527) (2105), pMEK1/2 (9121) and pERK (197G2) from
Cell Signaling (New England Biolabs Ltd., Pickering,
ON); and, uPAR (MAB807) antibody from R&D (R&D
Systems, Inc., Minneapolis, MN). Collagen (type I and
IV), fibronectin (FN), vitronectin (VN), fibrinogen (Fg)
and an antibody against vinculin (hVIN-1) were obtained
from Sigma (Sigma Chemical Co., St. Louis, MO).
Cells and Cell culture
All the cell lines were from ATCC. MDA-MB-435,
MDA-MB-231, and Hek-293 cells were cultured in
RMPI 1640, and MCF7 cells in F-12 containing 10%
fetal calf serum and 100 U/ml penicillin and 100 μg/ml
streptomycin. All cells were grown as monolayers on tis-
sue culture plates at 37°C in a humidified incubator with
5% CO2 and 95% air. Cells were subcultured at 80-95%
confluence using 0.25% trypsin (w/v)/5 mM EDTA to
detach cells.
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Cells were grown in 100 mm tissue culture plates to 90-
95% confluence and harvested with 2% EGTA. For mea-
surement of integrin expression, once harvested all sam-
ples were maintained at 4°C to maintain the expression
of integrins on the cell surface. Thus, cells were washed
and re-suspended in 4°C Tyrode-Hepes Buffer contain-
ing 1 mM CaCl2,1m MM g C l 2,5 . 5m MG l u c o s ea n d1
mg/ml BSA. Cells were incubated with primary antibo-
dies for one hour at 4°C, washed three times with ice-
cold Tyrode-Hepes Buffer and incubated with PE or
Alexa Fluor-488 labeled secondary antibody for another
one hour at 4°C. Cells were washed, re-suspended in 0.5
ml of ice-cold Tyrode-Hepes Buffer and kept on ice
until analyzed by flow cytometry. Isotype-matched
monoclonal antibodies were used as controls. For phor-
bol 12-myristate 13-acetate (PMA) treatment, cells were
grown for 16 hours in media containing 1% fetal calf
serum and then the cells were treated with 150 nM
PMA for two hours. For mock treatment, the cells were
incubated with the same concentration of DMSO as was
present in the PMA samples. Data was analyzed using
Flowjo program.
Adhesion Assay
Adhesion assays were performed as previously described
with minor modifications [18,19]. Briefly, 96-well plates
were coated with 20 μg/ml of collagen, FN, Fg or VN
overnight at 4°C. The wells were blocked with 2% BSA
and washed with PBS. MDA-MB-435, MDA-MB-231,
MCF7 or Hek-293 cells were suspended in serum free
media, with or without the addition of 150 nm PMA.
The cells were then transferred to the wells (2 × 10
5
cells/well) and incubated for one hour at 37°C. Unat-
tached cells were removed by washing with PBS and the
cells were then incubated in staining solution (20%
methanol, 1% formaldehyde and 0.5% crystal violet in
H2O) for 30 min. Plates were washed, lyzed in 0.5% Tri-
ton X-100, and adhered cells quantitated by measuring
light absorbance at 590 nm.
Western blotting
Cells were grown to 90-95% confluence, washed with
ice-cold PBS and lyzed in 500 μl of RIPA buffer (50
m MT r i s ,p H8 ,1 5 0m MN a C l ,0 . 1 %S D S ,0 . 5 %N a
deoxycholic Acid, 1% NP-40 or IGEPAL, 10 μg/ml apro-
tinin and 10 μg/ml leupeptin), and using a 25 gauge
needle. Cell extracts were centrifuged and supernatants
kept at -20°C. Equal amounts of protein (24 μg/well)
were electrophoretically separated in SDS polyacryla-
mide gels and proteins were transferred to a nitrocellu-
lose membrane. Membranes were blocked with 5% skim
milk and probed with primary antibodies, followed by
incubation with HRP-labeled secondary antibodies.
Western blots were visualized by an enhanced chemilu-
minescence detection system according to the manufac-
turer’s protocol (Amersham Life Sciences, Arlington
Heights, IL).
Immunofluorescence
Falcon 4-well CultureSlides were treated with 1% SDS,
rinsed with PBS and then coated overnight at 4°C with
20 μg/ml of collagen, FN, Fg or VN. Cells were seeded
and grown overnight on different ligand-coated chamber
cells. Cells were fixed with 4% paraformaldehyde for 10
min, permeabilized with 0.2% (v/v) Triton X-100,
washed and then blocked with 1% BSA. Filamentous
actin (F-actin) was stained using Alexa Fluor 594 phal-
loidin (Invitrogen, San Diego, CA) for 30 min at a dilu-
tion of 1:40. Focal adhesions were stained using an
antibody to vinculin (Sigma Chemical Co., St. Louis,
MO), or to talin (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) at a dilution of 1:100 and a fluorescein-conju-
gated secondary antibody.
Results
Integrin expression
Previous studies have identified a linkage between the
expression of b1 and av integrins and breast cancer
[4,6]. In addition, cell agonists such as PMA that acti-
vate protein kinase C and induces phosphorylation of
pERK, promote integrin-mediated cell adhesion, focal
adhesion formation and cell signaling in many cell types
including cancer cells [19,20]. Therefore, we first identi-
fied an optimal concentration of PMA that induced
pERK formation (Figure 1) and then assessed the rela-
tive levels of these integrins expressed by adhered breast
cancer cells and Hek-293 cells using flow cytometry of
untreated (Figure 2A) and PMA treated cells (Figure
2B). To determine the optimal concentration of PMA to
use, MDA-MB-435 cells were stimulated with different
concentrations of PMA (50 to 200 nM) and then the
level of pERK was determined by western blot analysis
(Figure 1). Results indicated that 150 nM PMA pro-
duced the highest levels of pERK, in agreement with our
previous studies using similar concentrations of PMA as
an activator of cell adhesion in other cell lines [18,19].
Therefore, 150 nM PMA was used as the PMA stimulus
in the remaining experiments.
To maintain the integrity of the surface expression of
integrins on cell adhered to FN, all cells washes and
incubations were performed at 4°C prior to their analy-
sis by flow cytometry. We consistently found that the
non-breast cancer cell line, Hek-293, generally expressed
lower integrin levels as compared to the three breast
cancer lines (Figure 2A). Hek-293 expressed very low
levels of b3, b5, avb3, avb5 and avb6, but higher levels of
b1 and av. All three breast cancer cell lines expressed
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levels of b5 and avb5 in comparison to Hek-293. MDA-
MB-435 integrin expression distinguished this cell line
from all others as they consistently expressed higher
levels of integrins and they were the only cell line to
express high levels of b3 and avb3.
Next, the effect of short-term PMA stimulation on
integrin expression in the cancer and Hek-293 cells was
evaluated (Figure 2B). The results obtained for PMA
treated cells were nearly identical to those of mock
DMSO treated cells and untreated cells (panel A). Integ-
rin expression remained unchanged or was only slightly
altered by PMA treatment. These results are consistent
with previous findings that short-term PMA treatment
does not enhance integrin expression [20], rather it acti-
vates integrins [18]. In addition, we determined that
short-term suspension or adhesion of cells in the pre-
sence or absence of PMA did not affect integrin expres-
sion (experiments performed in duplicate or triplicate).
For example, expression of avb3 in MDA-MB-231 sus-
pension cells treated with DMSO or PMA was 9.7% and
9.9%, respectively, and expression of avb3 in two hour
adhered MDA-MB-231 cells was 2.5% and 2.8%.
Furthermore, the expression of avb3 in MDA-MB-435
suspension cells treated with DMSO or PMA was 99.1%
and 98.2%, respectively, and expression of avb3 in two
hour adhered MDA-MB-435 cells was 98.4% and 98.8%.
Adhesion of breast cancer cell lines
Cell adhesion plays a vital in the survivability and pro-
gression of a cancer as engagement of integrins with the
ECM prevents some cancers from undergoing apoptosis
while it induces cell proliferation in others. In metastatic
cancers, cell adhesion undergoes rapid regulatory
changes that allow the cancer cell to disengage from the
ECM, migrate and then reengage with the ECM at its
secondary metastatic site. In addition, short-term expo-
sure of cells to cell agonists such as PMA, results in
increased av integrin-mediated cell adhesion and
spreading onto ECM proteins [19,20]. Therefore, we
assessed the capacity of 150 nM PMA to influence the
adherence of the breast cancer cells to ECM proteins
(Figure 3). We used FN, Fg and VN as ligands with dif-
fering specificity for av integrins and collagen as a non-
av integrin ligand. In general, the adhesion of unstimu-
lated cells, cells incubated in media alone, was markedly
greater than we previously reported for GM1500 or
M21 cancer cells [18,19], with 20 to 40% of the total
cells adhering within one hour. The majority of cells
that adhered within one hour were firmly attached and
cell spreading (formation of lamellipodia and filopodia)
was readily detected (data not shown). Unstimulated
MDA-MB-435 (Figure 3A) and MDA-MB-231 (Figure
3B) cell adhered highest to FN, while MCF7 (Figure 3C)
and Hek-293 cells (Figure 3D) had equal preference for
FN, Fg and VN. MDA-MB-231 showed the lowest non-
specific binding to BSA, and MCF7 cells were the only
cell line that adhered well to collagen. However, in con-
trast to our previous studies using avb3-expressing
GM1500 cancer cells [18], PMA treatment did not upre-
gulate cell adhesion. Increasing the PMA treatment and
adhesion time to four hours also showed no PMA effect
(data not shown). The adhesion of mock treated cells,
incubated with the same concentration of DMSO as was
Figure 1 Optimal PMA treatment concentration for pMEK and pERK activation. Cells were plated and grown overnight in media
containing 1% fetal calf serum, except for control cells that were grown in regular media containing 10% fetal calf serum. Cells were then
treated with increasing amounts of PMA (50-200 nM) for two hours. Additional control cells were incubated for one hour with the same
concentration of DMSO as present in the PMA samples (DMSO). Cells were lyzed, and equal amounts of total protein of each sample were
subjected to immunoblotting with antibodies against ERK and pERK. Two representative experiments are shown.
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Figure 2 Integrin expression by breast cancer and Hek-293 cells. A) Flow cytometric analysis of untreated cultured cells. Cells adhered to
FN-coated dishes were harvested and incubated with the mouse anti-human b1, b3, b5, av ,avb3 ,avb5 and avb6 antibodies, followed by
incubation with fluorescent-labeled secondary antibody and then analyzed by flow cytometry (black lines). Isotype-matched irrelevant antibodies
were used as controls (grey lines). B) Flow cytometric analysis of integrin expression by PMA stimulated cells. Adhered cells were incubated
overnight in media containing 1% fetal calf serum and then stimulated with 150 nM PMA for two hours. The cells were then harvested and
integrin expression levels assessed as described in panel A. In control plates (mock treatment), an equal quantity of DMSO was added instead of
PMA. One of three representative experiments is shown.
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unstimulated cells (data not shown). Therefore, we
tested the hypothesis that the non-PMA treated cells
were already near maximal levels of adhesion which
negated any further increase with PMA treatment.
Using GM1500 cells, we observed that less than 5% of
the non-treated cells adhered to Fg, and the cell adhe-
sion increased two to four-fold following PMA treat-
ment (data not shown). These results led us to conclude
that the breast cancer and Hek-293 cells expressed an
integrin co-receptor or a non-integrin adhesion receptor
that upregulated or directly facilitated cell adhesion. To
determine to what extent the adhesion was mediated by
integrins, the cells were allowed to adhere to FN for one
and two hours in the absence and presence of av and b1
functional-blocking antibodies. The adhesion of MDA-
MB-435, MDA-MB-231, MCF7 and Hek-293 cell after
one hour was inhibited 79.1% ± 8.8; 79.8% ± 8.4; 42.3%
± 24.5; 80.7% ± 8.7 (mean ± stdev), respectively by the
addition of both antibodies (n = 5 in duplicate experi-
ments). At two hours the adhesion was inhibited 82.5%
± 7.25; 75.4% ± 11.4; 64.5% ± 14.7; and, 90.2% ± 4.9,
respectively. Thus, MDA-MB-435, MDA-MB-231 and
Hek-293 cell adhesion was highly integrin-mediated,
while only two-thirds of MCF7 adhesion was integrin-
mediated. This led us to speculate that the increase in
adhesive capacity of these cell lines was a result of
increased integrin activation through the action of either
a co-receptor or upregulated signaling through intracel-
lular pathways.
Agonist-induced signaling
Cells continuously respond to their extracellular envir-
onment and cues provided by ECM proteins, growth
factors, cytokines and other cell agonists can invoke
varying responses within different cell types. Thus, some
of the heterogeneity of breast cancer could be a result
of varying responses by different breast cancer cells.
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Figure 3 Cell adhesion to various ECM integrin ligands. Cells (A, MDA-MB-435; B, MDA-MB-231; C, MCF7; and D, Hek-293) were harvested
and then untreated (grey box) or 150 nM PMA-treated (black box) cells were allowed to adhere to the plates coated with various ECM proteins
for 1 hour. The plates were washed and the number of adhered cells was calculated as a percentage of total added. Mock treated cells,
incubated with the same concentration of DMSO as was present in the PMA samples, had similar levels of adhesion as untreated cells (data not
shown). One of four representative experiments performed triplicate is shown.
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responded in a similar manner to a cell agonist. Further-
more, as integrins are responsible for transmitting sig-
nals from the environment to the cell, we also
determined if the high adhesion of unstimulated breast
cancer cells resulted in upregulated intracellular signal-
ing. We therefore allowed the cells to adhere overnight
onto FN-coated plates and then measured the levels of
integrin signaling molecules before and for various
times after treatment with 150 nM PMA. MEK levels
were unchanged by PMA treatment in MCF7 and Hek-
293 cells, and only decreased in MDA-MB-435 and
MDA-MB-231 cells after two hours of treatment (Figure
4A). However, marked changes occurred in the levels of
activated pMEK (S217/S221). In MDA-MB-435 cells,
pMEK levels in untreated and PMA treated cells
remained high until 2 hours of PMA treatment and
then decreased, while in MDA-MB-231 cells pMEK
levels remained higher and unaltered by PMA treat-
ment. The pattern of pMEK expression in MCF7 cells
was markedly different from the metastatic cells. All
non-PMA treated MCF7 cells (lanes 1-3) containing
undetectable levels of pMEK, and only a weak transient
signal was detected following PMA treatment. The pat-
tern of pMEK expression in Hek-293 was similar to that
of MCF7 cells. Furthermore, regardless of the differ-
ences in pMEK levels following PMA treatment, high
pMEK levels in adhered MDA435 and MDA231 cells
separated these metastatic cells from the non-metastatic
MCF7 and Hek293 cells.
PMA treatment had no effect on the high levels of
ERK present in each cell line (Figure 4B). In contrast,
the levels of activated pERK were very low in most of
the non-treated cells and PMA treatment resulted in
differential upregulation of pERK. The levels of pERK in
MDA-MB-435 cells transiently increased in a biphasic
response to PMA, reaching maxima at 30 min and two
hours. In MDA-MB-231 cells, pERK levels never
reached a maximum, while pERK levels in MCF7 cells
increased between 30 min and two hours. There was
high and sustained induction of activated pERK in Hek-
293 cells following PMA treatment (Figure 4B). Thus,
there was heterogeneity in MAPK pathway signaling by
adhered breast cancer cells in the absence and presence
of PMA.
The Src pathway was investigated in the cells by eval-
uating their levels of c-Src, activated Src [pSrc(Y416)]
and deactivated Src [pSrc(Y527)]. The levels of c-Src
remained unchanged in MCF7 and Hek-293 cells, while
they decreased after two hours of PMA treatment in the
metastatic MDA-MB-435 and MDA-MB-231 cells (Fig-
ure 4C). PMA induced activation of Src in MDA-MB-
435 cells, with pSrc(Y416) levels reaching at maxima at
two hours. There was minimal induction of pSrc(Y416)
in MDA-MB-231, MCF7 and Hek-293 cells. In addition,
all cells grown in media containing 10% fetal calf serum
that supports cell proliferation (lane one) contained
higher levels of activated pSrc(Y416) than when grown
in 1% fetal calf serum (lanes 2-7). This cell proliferation
effect was not observed for any of the other signaling
proteins examined. To confirm that these cell lines
expressed low levels of activated pSrc in 1% fetal calf
serum, we also measured the level of pSrc(Y416) in
aIIbb3-expressing Chinese hamster ovary (CHO) cells
adhered to Fg (Figure 4D). Here, pSrc(Y416) levels were
readily detected and upregulated. The levels of deacti-
vated pSrc(Y527) in MDA-MB-435 and MDA-MB-231
cells also reached a maximum at two hours, while they
increased in MCF7 cells after two hours. In contrast to
the cancer cells, Hek-293 cells expressed high and unal-
tered levels of deactivated Src.
FAK levels remained unchanged in all cell lines,
except after two hours of treatment in MDA-MB-435
cells (Figure 4E). The levels of activated pFAK also
remained unaltered in MCF7 and Hek-293 cells but did
transiently increase at two hours in MDA-MB-435 cells,
which correlated with maximal levels of pERK and pSrc
(Y416). MDA-MB-231 pFAK levels increased after one
hour which correlated only with their pERK levels.
Therefore, we observed heterogeneity in MAPK and Src
signaling by the breast cancer cells.
Immunocytochemistry
Integrin signaling is complex as it not only governed by
the binding of an ECM ligand but it is also regulated by
the recruitment and interaction of integrin-associated
proteins with integrin clusters and the formation of
integrin-based structures, such as focal adhesions. As
adhered breast cancer cells differed in their signaling
(Figure 4), we investigated if these differences in signal-
ing were due to changes in integrin-based structures.
Therefore, experiments were performed to determine
whether the differences were due to changes in the sub-
cellular distribution of F-actin stress fibers or the forma-
tion of focal adhesions when the cells were allowed to
attach to and spread on ECM ligands (Figure 5). The
cells were plated onto coverslips coated with collagen,
Fg, FN or VN, and allowed to adhere overnight. Cells
were fixed, permeabilized, and stained for F-actin and
focal adhesions. F-actin stress fibers were easy to iden-
tify and major differences in the distribution and organi-
zation of F-actin fibers were observed (Figure 5A). In
MDA-MB-435 cells adhered to the four ECM ligands,
m a n yb u n d l e so fs t r e s sf i b e r ss p a n n i n gt h ec o r eo ft h e
cells were observed, and adherence to FN and VN
induced the greatest formation of stress fibers. In MDA-
MB-231 cells, F-actin was mainly present at the peri-
meter of the cell and localized to membrane protrusions
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MDA-MB-231 cells contained more and denser cluster-
ing of the protrusions than MDA-MB-435 cells. The
distribution of F-actin in MCF7 was condensed and
localized to the leading edge of spreading cells. In con-
trast, Hek-293 cells were almost devoid of stress fibers.
Vinculin is a prominent component of focal adhesions
and it induces integrin clustering and focal adhesion for-
mation through interactions with talin, an actin-integrin
linkage protein [21]. Therefore, focal adhesions were
visualized using vinculin staining (Figure 5B). Compared
to the three other cell lines, MDA-MB-435 adhered to
Figure 4 Effect of PMA treatment on the expression of signaling proteins. All cells were plated and grown overnight in media containing
1% fetal calf serum, except for a control cells that received no treatment (NT) and were grown in media containing 10% fetal calf serum. Cells
were then treated with 150 nM PMA for times indicated. Additional control cells were incubated for one hour with either media alone (Media),
or with the same concentration of DMSO as was present in the PMA samples (DMSO). Cells were lyzed, and equal amounts of total protein of
each sample were subjected to immunoblotting with antibodies against (A) MEK and pMEK; (B) ERK and pERK; (C) c-Src, pSrc(Y416) (pY416) and
pSrc(Y527) (Y527); or (E) FAK and pFAK. Western blots of (D) pSrc(Y416) in Chinese hamster ovary (CHO) cells expressing aIIbb3 and adhered to
Fg are also displayed for comparison. One of three representative experiments is shown.
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Page 8 of 15the four ECM ligands show enhanced focal adhesion
formation, which correlated with the presence of strong
stress fibers. Some focal adhesions were found distribu-
ted at the periphery of MCF7 cells, while only FN
induced the formation of a few focal adhesions in
MDA-MB-231 cells. No focal adhesions were detected
in Hek-293 cells.
The staining pattern with anti-talin was similar to that
of vinculin (Figure 5C). As talin is reported to be both
an integrin-linkage protein and an integrin activator
[22], its recruitment to focal adhesions also serves as a
mechanism for focal integrin activation and signaling. In
MDA-MB-435 and MCF7 cells adhered to any of the
ligands, talin staining revealed a diffuse distribution of
Figure 5 Immunocytochemistry of actin stress fibers and focal adhesions. Chamberslides were coated with 20 μg/ml of collagen, Fg, FN or
VN and then MDA-MB-435, MDA-MB-231, MCF7 or Hek-293 cells (1 × 10
5/slide) were seeded and allowed to adhere overnight. The slides were
washed, fixed, permeabilized and then stained for F-actin (A), vinculin (B) and talin (C). One of four representative experiments is shown.
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Page 9 of 15talin within the cytoplasm and a strong recruitment of
talin to focal adhesions localized to lamellipodia and
filopodia. In MDA-MB-231 cells adhered to collagen, Fg
and VN, very few focal adhesions were detected using
talin staining. However, a dot-like distribution pattern
resembling focal complexes was observed in MDA-MB-
231 cells adhered to FN. Hek-293 cells did not form any
focal adhesions and cell spreading was much higher on
FN than on the other ligands. Therefore we observed
that MDA-MB-435 cells expressed the highest level and
organization of actin-integrin linkage structures and
focal adhesions. The higher level of focal adhesions in
the MDA-MB-435 cells is consistent with our observa-
tion that this cell line had the strongest correlation
between PMA-induced activation of pFAK, pSrc(416)
and pERK (Figure 4). Furthermore, our MDA-MB-435
data is consistent with previous findings that higher
expression levels of integrin avb3, are associated with
well-developed focal adhesions and thicker stress fibers
in primary breast cancer cells compared with the normal
breast epithelial cells [23]. Finally, we also observed that
a two hour treatment of cells with PMA induced stress
fiber perturbations in all cell lines, loss of focal adhe-
sions in MDA-MB-435 cells and induced some MCF7
cells into apoptosis (data not shown).
uPAR and VEGFR expression
Integrin signaling is a dynamic process, being influenced
by a number of factors including the cross-talk with
other cell surface receptors, such as uPAR and VEGFR.
These two receptors are also implicated in breast cancer
tumor progression and invasiveness. Signaling by uPAR
requires interactions with integrin or other co-receptor
as it lacks a transmembrane and an intracellular domain
[14]. uPAR also contributes to breast cancer develop-
ment by directly supporting cell adhesion to VN, and by
coordinating ECM proteolysis and remodeling through
activation of plasmin and breakage of integrin-ECM lin-
kages that allow for cell migration and metastasis [14].
The interaction of VEGFR with integrins, such as avb3,
avb5 and a5b1, is involved in cancer-induced angiogen-
esis that facilitates the growth and progression of breast
cancers [11]. Therefore, the levels of uPAR and VEGFR
expressed by the cell lines were determined (Figure 6).
The breast cancer and Hek-293 cells all expressed
uPAR, with MCF7 expressing slightly higher levels of
uPAR than MDA-MB-231 and MDA-MB-435 cells (Fig-
ure 6). As all cells, and in particular MCF7 cells,
adhered well in the absence of an agonist (Figure 3), we
questioned whether uPAR may have been involved in
the upregulated adhesion. To address this question we
also determined the levels of uPAR in GM1500 cells
which we demonstrated had low adherence in the
absence of a cell agonist. However, we found that uPAR
levels in GM1500 cells were similar to those of MDA-
MB-231 and Hek-293 cells (Figure 6). This led us to
conclude that the levels of uPAR expressed in MDA-
MB-231 and Hek-293 cells were insufficient to upregu-
late cell adherence. In contrast to uPAR expression,
VEGFR expression varied greatly between the cell lines
(Figure 6). MCF7 cells expressed greater than 10-fold
more VEGFR compared to MDA-MB-435 and GM1500
cells, while MDA-MB-231 and Hek-293 cells expressed
low to moderate amounts, respectively. In addition, we
determined that all cell lines produced very low
amounts of VEGF (data not shown). Thus, MCF7 cells
were readily distinguished from the metastatic cells
based upon their expression of VEGFR.
uPAR
VEGFR
Hek-293 MDA-231 MDA-435 MCF7 GM1500
Figure 6 uPAR and VEGFR expression. The level of uPAR and VEGFR expression (black lines) in unstimulated MDA-MB-435, MDA-MB-231,
MCF7, Hek-293 cells and GM1500 cells were assessed by flow cytometry using anti-uPAR and VEGFR antibodies as described in Figure 1. Isotype-
matched irrelevant antibodies were used as controls (grey lines). One of three representative experiments is shown.
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During the adherence of a cell to the ECM, integrins
interact with a number of matrix and cellular proteins
that result in the activation of signaling pathways result-
ing in changes in cellular function and biology. As the
breast cancer cells used in this study differed in their
capacity to form focal adhesions, we explored the possi-
bility that part of the heterogeneity of breast cancer was
due to variations in adhesion-induced signaling through
MAPK and Src pathways by different breast cancers. In
looking at the Src pathway, we discovered that Src was
highly deactivated in all cell lines and that the level of
pSrc(Y527) and c-Src were unchanged by adherence to
ECM proteins (data not shown). Therefore, we focused
our attention on the MAPK pathway by first ascertain-
ing if there was constitutive signaling from integrins
through to ERK by measuring the levels of pFAK,
pMEK, and pERK in non-adherent suspension cells (Fig-
ure 7A). All cancer cells contained activated pFAK,
pMEK, and pERK in suspension, with MDA-MB-231
cells expressing much greater levels of pFAK and
pMEK. Hek-293 suspension cells contained very low
levels of pMEK and pERK, and typical of a nonadherent
cell, they contained undetectable levels of pFAK.
As MDA-MB-231 suspension cells expressed the high-
est levels of pFAK and pMEK, but MDA-MB-435
expressed the highest levelsp E R K ,w ef u r t h e ri n v e s t i -
gated the differences in their regulation of MAPK path-
way using adhered cells (Figure 7B). Adhered MDA-
MB-231 cells contained higher levels of pFAK compared
to MDA-MB-435 cells, but only MDA-MB-435 cells
exhibited a slight but reproducible adhesion-dependent
increase in pFAK. This result was consistent with
MDA-MB-435 cells containing more focal adhesions
than MDA-MB-231 cells (Figure 5). Adhesion of MCF7
cells to ECM ligands resulted in only small changes in
pFAK, while Hek-293 cells contained no pFAK (Figure
7B). The absence of activated pFAK in Hek-293 cells
was consistent with this cell line containing no focal
adhesions. The levels of pMEK and pERK in non-meta-
static MCF7 cells clearly distinguished this cell line from
the metastatic MDA-MB-435 and MDA-MB-231 cells.
Figure 7 Adhesion induced signaling of Hek-293 and breast cancer cells. Cells were either left in suspension or placed into wells coated
with BSA, collagen (Coll), Fg and FN. After a one hour incubation at 37°C, plates were washed to remove non-adhered cells. Total cellular
protein was then extracted from adhered and suspension cells and subjected to immunoblotting with antibodies against pFAK, pMEK and pERK
as described in Figure 3. Blots for suspension cells are displayed in panel A. Blots for suspension and adhered cells are displayed in panel B. FAK,
MEK, ERK, c-Src and pSrc levels were also assessed and remained unchanged (data not shown). (C) Samples were also probed using antibodies
against Bcl2 and activated pErbb2. One of three representative experiments is shown.
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levels of pMEK and pERK, while MDA-MB-435 and
MDA-MB-231 cells contained high levels of both these
proteins. Most adhered Hek-293 cells contained low but
detectable levels of pMEK and pERK, and pERK levels
increased following adhesion.
Adhesion-induced changes in pMEK and pERK levels
also distinguished MDA-MB-435 from MDA-MB-231
cells (Figure 7B). There was an adhesion-dependent
increase in pMEK levels in MDA-MB-435 cells, but not
in MDA-MB-231 cells. It also appeared that there was
constitutive activation of pMEK in MDA-MB-231 cells,
as the level of pMEK in suspension cells were similar to
those found in adhered MDA-MB-231 and MDA-MB-
435 cells. However, once again, high pMEK levels in
adhered metastatic MDA435 and MDA231 cells sepa-
rated these cells from non-metastatic MCF7 and
Hek293 cells. The effects of adhesion on the level of
pERK in MDA-MB-435 and MDA-MB-231 cells con-
trasted those of pMEK. Here we observed an adhesion-
dependent increase in pERK levels in MDA-MB-231
cells, but not in MDA-MB-435 cells. These differences
were not due to changes in total FAK, MEK or ERK
levels which remained unaltered (data not shown). As
ERK is immediately downstream from MEK, we specu-
late that the differences in pERK levels were due to dif-
ferences in the regulation of pERK-related phosphatase
activity within these cells. In MDA-MB-231 cells, we
propose that adhesion suppresses phosphatase activity
allowing for pERK levels to increase, while in MDA-
MB-435 cells, either adhesion increases phosphatase
activity or pERK levels in suspension cells are already at
maximal. Whatever explanation is correct, there were
differences in MAPK signaling between MDA-MB-435
and MDA-MB-231 cells and a marked reduction in
MAPK signaling by MCF7 cells. We also noted that
there are likely other non-integrin receptors involved in
cell adhesion-induced signaling as adhesion to BSA
resulted in increased pFAK, pMEK and pERK levels in
some cell lines.
We also examined the effect of cell adhesion on Bcl2
and pErb2 levels. Bcl2 is an important regulator of
apoptosis and Bcl2 itself is regulated by integrin signal-
ing. pErbB2 is involved in signal pathways leading to
cell growth and differentiation which are two cellular
processes regulated by integrin signaling. Therefore, we
determined the effect of cell adhesion on Bcl2 and
pErb2 levels to identify any correlations in changes in
their levels to that of pMEK, pERK or pFAK. Bcl2 levels
were unaffected by cell adhesion, and similar to the
levels of phosphorylated kinases, no major differences in
Bcl2 levels were found in cells adhered to FN versus Fg
or collagen. MDA-MB-435 expressed the highest levels
Bcl2, but expressed the lowest level of activated pErbB2.
MDA-MB-231 and MCF7 cells expressed similar
amounts of pErbB2 while Hek-293 cells expressed the
lowest, in agreement with pErbB2 being a prognostic
marker for some breast cancers.
Discussion
Integrins play an important role in cell anchorage,
migration, differentiation and death [5,7], and their
upregulated expression in human cancers frequently
indicates poor prognosis. Although breast cancer is a
heterogeneous form of cancer, av integrins as well as
other proteins have been identified as prognostic mar-
kers. In the present study, using two metastatic (MDA-
MB-435 and MDA-MB-231) and a non-metastatic
(MCF7) breast cancer cell line, we demonstrated that av
integrin expression varies between the cell lines (Figure
2A). This variation may partially account for the hetero-
geneity that is found in breast cancer. In comparison to
the non-breast cancer Hek-293 cells, all the cancer cells
expressed higher but varying levels of b5, avb5 and avb6.
Normal epidermal cells express avb5 but after trans-
forming into squamous carcinomas, the expression of
avb5 is down-regulated and avb6 up-regulated that pro-
tects the cancer from undergoing anoikis [24]. Thus, dif-
ferences in avb5 and avb6 expressions may account for
some of the heterogeneity in the phenotypes of breast
cancers. Furthermore, we found that only MDA-MB-
435 cells expressed high levels of b3 and avb3.I nv i v o
studies reveal that avb3 is also involved in enhanced
metastasis of breast cancer to bone [25]. The high levels
of b3 and avb3 in metastatic MDA-MB-435 cells is in
keeping with b3 being an important mediator of mela-
noma cell invasion and migration and with avb3 as a
prognostic indicator in breast cancer [4,5,26,27]. How-
ever, as MDA-MB-231 and MCF7 cells did not express
avb3, avb3 should not be viewed as a universal prognos-
tic indicator for all forms of breast cancer. Rather, it
should be used as an indicator where the use of anti-
avb3 therapeutics is warranted.
Integrins, play a significant role in the acquisition and
maintenance of neoplastic phenotype by preventing
apoptosis and maintaining cell proliferation, and integrin
expression profile can dramatically change upon the
normal-to-neoplastic transition [6]. However, we found
that short term (one to two hours) of adhesion onto FN
or Fg had minimal effect on integrin expression in
MDA-MB-432, MDA-MB-231 and MCF7 cells. Thus, it
is likely that changes in integrin expression profile dur-
ing cancer cell metastasis may either require more time
or may also require the activity of matrix-degrading pro-
teases, such as uPA and matrix metalloprotease 2, to
modify the surrounding tissue [5].
In nonmalignant and cancer cells, integrin-mediated
adhesion of unstimulated cells is usually low and can be
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PMA [18,19]. In this study, we found that the adhesion
of unstimulated breast cancer and Hek-293 cells was
already upregulated, and that level of uPAR expressed
by the cells (Figure 6) was likely not sufficient enough
to upregulate cell adhesion. However, all cell lines when
adhered and proliferating constitutively expressed acti-
vated pSrc (Figure 4C, lane 1), which may have been
influenced by uPAR-integrin interaction, or in MDA-
MB-435 and Hek-293 cells, partially a result of Src sig-
naling following its direct binding to b3 [13,14]. Adhe-
sion to VN is mediated by uPAR [14] and by a number
of integrins including avb1, aIIbb3, avb3, avb5, avb6 and
avb8 [28]. Similarly, other integrins also share common
ligands, which likely accounts for why we did not
o b s e r v eas t r o n gp r e f e r e n c ef o ro n eE C Ml i g a n d .I n
addition, non-integrin adhesion receptors also contribu-
ted to cell anchorage as all cells, except MDA-MB-231,
adhered to BSA.
The formation of focal complexes, focal adhesion and
other integrin-related cellular structures has a profound
effect on cell shape and numerous cellular processes
that govern the biology of a cell [12]. Our vinculin and
talin staining produced similar results which agree with
the role of vinculin in controlling focal adhesion forma-
tion by directly interacting with talin [21]. F-actin and
focal adhesion staining demonstrated that the non-
breast cancer cell line, Hek-293, was nearly devoid of
integrin-associated structures in comparison to the
breast cancer lines (Figure 5). We also observed that a
two hour PMA treatment induced stress fiber perturba-
tions in all cell lines, and resulted in a loss of focal
adhesions in MDA-MB-435 cells. These results are con-
sistent with previous findin g st h a tP M A - m e d i a t e dF -
actin reorganization and redistribution is closely linked
with cell transformation [29]. We also concluded that
some of the heterogeneity of breast cancer can be
explained by variations in the level of integrin-asso-
ciated F-actin structures between different breast can-
cers. MDA-MB-435 cells contained numerous well
defined stress fibers that protruded into the cell interior
and formed numerous focal adhesions. These features
readily differentiated MDA-MB-435 cells from the other
breast cancer cells. It also appears that MDA-MB-435
focal adhesions were signaling effectively as evident with
the correlated transient increases in pFAK, pSrc(Y416)
and pERK following PMA treatment (Figure 4), and in
the adhesion-induced activation of pFAK and pMEK
(Figure 7).
The integrin co-receptors, uPAR and VEGFR, play
important roles in the progression of cancers [11,14].
All the breast cancer cell lines and Hek-293 cells
expressed uPAR but only MCF7 cells expressed high
levels of VEGFR. The expression of uPAR by all the
cancer lines, is in keeping with uPA/uPAR being a prog-
nostic marker of breast cancer. uPAR participates in
many cellular processes by interacting with b1 and b3
integrins and modulate their signaling, by serving as a
binding site for VN and by inducing cytoskeletal reorga-
nization [14,30]. The delivery of an adequate supply of
blood to malignant tumors is required for their rapid
expansion as they must receive nutrients and oxygen
imposed by tumor growth [11]. Many cancers meet
their blood supply demands by inducing angiogenesis,
and there is increasing evidence implicating integrin sig-
naling, generated by interactions with ECM proteins and
with VEGFR, as a major modulator of cancer-induced
angiogenesis [4,11]. The high expression of VEGFR by
the non-metastatic MCF7 cells, may indicate a critical
role for angiogenesis in the progression of MCF7 breast
cancers. In MDA-MB-435 and MDA-MB-231 metastatic
tumors, uPAR-mediated degradation and remodeling of
the ECM to facilitate metastasis [14], is likely of more
importance than VEGFR-mediated angiogenesis in the
progression of these cancers.
Breast carcinomas have been reported to contain
higher MAPK activity than benign breast tissue, and
there is a positive correlation between ERK activation
and shorter relapse-free survival period [31,32]. Other
studies reported a positive correlation between ERK
activation and a less aggressive disease and better survi-
val rates [33]. The magnitude and temporal organization
of ERK activity also correlates with specific biological
responses [34,35]. In intestinal cells, transient ERK activ-
ity results in cell growth, while a strong and sustained
ERK activity leads to cell cycle arrest [35]. In our study,
we identified marked differences in the regulation of
MAPK signaling and ERK activation within the cancer
lines. The levels of pMEK and pERK in adhered MDA-
MB-435 and MCF7 cells were transient, reaching a max-
imum within two hours of PMA treatment, while pMEK
levels in MDA-MB-231 cells remained constitutively
high and pERK levels continued to increase. Further-
more, in contrast to MDA-MB-231 cells in which
pMEK levels were adhesion-independent and pERK
levels were adhesion-dependent, pMEK levels were
adhesion-dependent and pERK levels were adhesion-
independent in MDA-MB-435 cells. We speculate that
differences in the activity of phosphatases within the cell
lines accounted for the different pERK levels, and that
alterations in the regulation of phosphatase activity
between various breast cancers contributes to variations
in their phenotypes. Furthermore, our data supports a
relationship between pERK and the metastatic capacity
of the cells, as adhered metastatic MDA-MB-435 and
MDA-MB-231 cells contained elevated pERK levels
compared to non-metastatic MCF7 and Hek-293 cells
(Figure 7B).
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binding site for Src-family protein kinases which follow-
ing further activation, phosphorylates a variety of sub-
strates such as paxillin, and activates a number of
protein kinase cascades [12,36]. The expression of Src
correlates with metastatic activity of breast cancers, and
integrin signaling through Src can be FAK-mediated or
FAK-independent as Src in cancers expressing b3 integ-
rins [13,37]. In our studies, all proliferating cells
expressed activated pSrc(Y416) but only metastatic
MDA-MB-435 cells showed an induction of pSrc levels
following PMA stimulation. As this was the only breast
cancer to express avb3, we believe that FAK-indepen-
dent activation of Src by avb3 contributes to the meta-
static phenotype of MDA-MB-435 breast cancers.
The ability of metastatic cells to loosen their adhesion
to the ECM and acquire a migratory phenotype that
enables the cancer to move through and expand into
other tissues are processes regulated by FAK-Src signal-
ing [36]. High FAK expression occurs in cancers, includ-
ing breast cancers, and FAK expression is correlated with
a highly malignant and metastatic phenotype [38-40].
Our own observations are consistent with these previous
studies, with the breast cancers containing higher levels
of FAK than Hek-293 cells. In addition, pFAK levels were
markedly elevated in MDA-MB-231 cells, which may
reflect the invasive phenotype of this cancer [15]. The
higher levels of pFAK in MDA-MB-231 may contribute
to focal adhesion turnover and reorganization, resulting
in fewer stable focal adhesions and fewer contacts
between integrins and actin stress fibers. This speculation
is supported by our observation that MDA-MB-231 cells
formed the fewest focal adhesions of the three breast can-
cers, which may allow for them to more readily disengage
from the ECM. Their capacity to remodel and degrade
ECM, partially using uPAR-mediated processes, would
then facilitate their migration and invasion into other tis-
sues. Other studies have demonstrated that FAK-
mediated signaling to ERK does not follow a single linear
pathway [36]. FAK enhances the phosphorylation of
MEK1 at Ser-298 facilitating ERK2 activation [41]. Thus,
FAK signaling can potentially affect the tumorogenic,
metastatic, and invasiveness of breast cancers by modu-
lating Src and MAPK signaling.
Conclusion
Our study identifies that there is heterogeneity in integ-
rin expression, integrin cellular structures, integrin co-
receptor expression and integrin signaling within breast
cancers. This heterogeneity likely contributes to the
phenotypic heterogeneity of breast cancer. More studies
are needed to better define the role of integrin-asso-
ciated structures in regulating integrin signaling and the
role of integrin signaling in breast cancer metastasis and
invasiveness. Our data also underscores the need for
better categorization of breast cancers into smaller
groups to allow for more efficacious therapeutic
treatment.
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